HBSP (USA)
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Making Impact Investing Markets: IFC (A)
Cole, Shawn; Masko, John; Zochowski, T. RobertCase HBS-221061-EFinanceIn 2017, the International Finance Corporation (IFC) faced the first big investment decision in its new Scaling Solar project. Founded in 1956, IFC was an international investment body with national governments as shareholders, whose mission was to promotStarting at €8.20
-
Making Impact Investing Markets: IFC (B)
Cole, Shawn; Masko, John; Zochowski, T. RobertCase HBS-221081-EFinanceIn 2018, Thailand's Bank of Ayudhya (known as Krungsri), was considering whether to participate in the first issue of a new financial instrument from the International Finance Corporation (IFC), known as a gender bond. Building on the success of the GreenStarting at €5.74